GE-Intel venture to focus on new models of care delivery
SANTA CLARA, Calif. A new healthcare company focused on telehealth and independent living soon will be created, GE and Intel Corp. announced on Monday.
“New models of care delivery are required to address some of the largest issues facing society today, including our aging population, increasing healthcare costs and a large number of people living with chronic conditions,” stated Intel president and CEO Paul Otellini. “We must rethink models of care that go beyond hospital and clinic visits, to home and community-based care models that allow for prevention, early detection, behavior change and social support. The creation of this new company is aimed at accelerating just that.”
GE and Intel entered into a definitive agreement to form a 50/50 joint venture to create a new company that will be formed by combining assets of GE Healthcare’s Home Health division and Intel’s Digital Health Group, and will be owned equally by GE and Intel. Pending regulatory and other customary closing conditions, the joint venture is expected to become operational by the end of the year. Financial terms were not disclosed.
The new company will focus on three major segments — chronic disease management, independent living and assistive technologies. GE Healthcare and Intel will contribute assets in remote patient monitoring, independent living concepts and assistive technologies, such as the Intel Health Guide, Intel Reader and GE Healthcare’s QuietCare.
The venture builds on the GE-Intel healthcare alliance announced in April 2009 around independent living and chronic disease management. Once formed, the new company will develop and market products, services and technologies that promote independent living both at home and in assisted living communities.
The new company will have headquarters in the greater Sacramento, Calif. area. Louis Burns, currently VP and general manager of Intel’s Digital Health Group, will be CEO of the new company, and Omar Ishrak, SVP of GE and president and CEO, GE Healthcare Systems, will be chairman.
Bayer Diabetes Care updates devices under National Glycohemoglobin Standardization Program
TARRYTOWN, N.Y. Bayer Diabetes Care has successfully completed certification of its A1CNow+ and A1CNow Selfcheck devices under a tighter performance certification standard that went into effect Jan. 1.
The new performance certification standards applicable to devices that measure A1C (or glycated hemoglobin) as set by the National Glycohemoglobin Standardization Program (NGSP) changed to +/-0.75% A1C, 95% CI, 4-10.0% A1C range.
Bayer received a new NGSP certificate valid from July 1, 2010 through July 1, 2011. The previous criteria for last year’s NGSP certification was +/-0.85% A1C, 95% CI, 4-12.0% A1C range.
Study: Two therapies may slow diabetic retinopathy in Type 2 diabetes
WINSTON-SALEM, N.C. In high-risk adults with Type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.
Intensive blood-sugar control reduced the progression of diabetic retinopathy, compared with standard blood-sugar control, and combination lipid therapy with a fibrate and statin also reduced disease progression, compared with statin therapy alone. However, intensive blood pressure control provided no additional benefit to patients compared with standard blood pressure control.
Results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study, supported by the National Institutes of Health, recently were published in the New England Journal of Medicine and presented at the 70th Scientific Sessions of the American Diabetes Association.
"This is the largest study to date examining the effects of blood sugar, combination lipid therapy, and blood pressure control on the prevention of diabetic retinopathy progression using retinal photographs," stated Walter Ambrosius, a professor of biostatistical sciences in the Division of Public Health Sciences at Wake Forest University Baptist Medical Center and principal investigator of the ACCORD Eye study’s coordinating center, in a release issued Friday. "Many people with diabetes have microvascular problems, which can result in problems with the kidneys and amputation of toes and feet, and the only place that you can directly observe the microvasculature is in the back of the eyes. What we have seen in the eyes is potentially an indicator of what is happening in other parts of the body."
"The ACCORD Eye Study clearly indicates that intensive glycemic control and fibrate treatment added to statin therapy separately reduce the progression of diabetic retinopathy," added Emily Chew, chair of the Eye Study and chief of the Clinical Trials Branch of the Division of Epidemiology and Clinical Applications at the National Eye Institute. "The main ACCORD findings showed that fibrate treatment added to statin therapy is safe for patients like those involved in the study. However, intensive blood sugar control to near normal glucose levels increased the risk of death and severe low blood sugar, so patients and their doctors must take these potential risks into account when implementing a diabetes treatment plan."
The ACCORD study was a landmark clinical trial that included 10,251 adults with Type 2 diabetes who were at especially high risk for heart attack, stroke or cardiovascular death. The study evaluated three intensive strategies, compared with standard treatments for lowering cardiovascular risks associated with diabetes.